Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Bullboard Posts
Comment by Haidukon Jul 16, 2020 4:52pm
165 Views
Post# 31278193

RE:Corporate Update

RE:Corporate Update
Although management lost precious time (and our money) and needed a “pandemic in an unrelated disease to get them to look across the campus” (as previously mentioned by M101), this update presents a coherent strategy, complementing the company’s original focus, with elements (previously communicated) that might (if successful) set PMN in the spot light before the end of the year.

On the negative side, it is clear that management constantly failed to meet his own deadlines (including the so-called perpetual “near-term catalyst”, which never materialized) and, consequently, I remain extremely cautious about the planning presented on page 4 (except  for the Covid).

In short, I would have been on the buy side but, since management demonstrated a lack of transparency (if not a lack of respect to the shareholders) as regards to the cash (if any) obtained with the “repriced warrants”, I suspect that a PP is under preparation.  Therefore, in the absence of such transparency, I remain on the side line…

GLTA
Bullboard Posts